報價延遲最少15分鐘:2025/06/01 08:11 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
245.8 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.64/6.21
|
|
企業價值
26.88B
|
| 資產負債 |
|
每股賬面淨值
32.37
|
| 現金流量 |
|
現金流量率
0.01
|
| 損益表 |
|
收益
238.39M
|
|
每股收益
17.01
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/01 08:11 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies witha contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue. |